Euprotec collaborates with Fulhold and New Jersey Medical School in developing a novel agent to prevent multi-drug resistant skin infections
26th March 2013
The US Department of Defence (DoD) has awarded to New Jersey Medical School-UMDNJ and an international consortium consisting of Euprotec and Fulhold Ltd a $1.53 million contract (W81XWH-12-2-0076) to develop a new product that could save the lives and hasten recovery of soldiers on the front-line.
Euprotec, a UK-based specialist contract research organisation, is collaborating with Mauritius based Fulhold and the New Jersey Medical School-UMDNJ, following funding from the DoD, to evaluate a topical broad spectrum antimicrobial agent for use in US soldiers’ battle-packs. It is proposed that, when applied to a battlefield wound, the product will prevent a broad range of posttraumatic microbial infections, which could otherwise prove fatal if left untreated. This has the potential to not only save the lives of numerous soldiers but also to revolutionise the treatment of infections following trauma.
The Fulhold product, Carbohydrate Derived - Fulvic Acid (CHD-FA), has a novel mechanism of action with no reservoir of natural resistance. CHD-FA demonstrates potent broad spectrum antimicrobial activity against a large range of multidrug resistant Gram positive and Gram negative bacteria such as MRSA, NDM-1 positive E. coli, carbapenem-resistant Enterobacteriaceae (CRE), tuberculosis and pathogenic fungi.
The DoD contract has been awarded to fund extensive research, in order to accelerate the development of the product for treatment of US soldiers, in a bid to reduce the significant morbidity and mortality caused by traumatic wound infections.
CHD-FA is likely to be particularly suitable for use in soldiers’ battle-packs or first aid situations as it is safe and stable at high temperatures.
If successful, the program signals a significant breakthrough in the prevention of a broad range of difficult to treat infections. Ultimately the goal is to make the product available to the general population to effectively and conveniently prevent infections in wounds and serious burns.
Dr Lloyd Payne, chief executive officer of Euprotec commented: “We are delighted to be part of this prestigious DoD funded program and collaboration with the New Jersey Medical School and Fulhold. It is critical that we address antimicrobial resistance and CHD-FA offers significant potential for the prevention of serious wound infections. This award further validates our scientific capability and strong commitment to the infectious disease therapeutic area.”
Dr Peter Warn, chief scientific officer of Euprotec added: “The potential of CHD-FA holds significant promise. This product could revolutionise the treatment and prevention of wound infections and we are confident that by working with Fulhold and the New Jersey Medical School we will be able to rapidly develop this innovative product for clinical use.”
Professor David Perlin Ph.D, executive director of The Public Health Research Institute (PHRI) of New Jersey Medical School-UMDNJ said: “Wound infections among injured military combatants and the civilian population are increasingly resistant to existing drugs, which makes patient management problematic with more serious systemic complications. Early and effective treatment of wounds is the key to successful clinical management. We are delighted to have Euprotec and Fulhold as partners in this important program.”
Wally Strickland, a director at Fulhold Ltd, commented: “We have believed in the potential of CHD-FA to treat drug resistant wound infections for many years and have completed a number of research projects with Euprotec. We are honoured to be building on this work with partners of the calibre of Euprotec and Professor Perlin at the New Jersey Medical School.”
Euprotec is a world-leader in the provision of infectious disease and respiratory biology services. With a highly relevant and validated portfolio of assays and disease models, underpinned by internationally recognised expertise, the company supports each stage of client anti-infective drug discovery and development programs through to late stage preclinical investigation and clinical proof-of-concept studies.
Euprotec’s extensive collection of bacterial and fungal strains/clinical isolates underpins its comprehensive range of drug discovery services consisting of a full range of preclinical efficacy models of bacterial/fungal infection; PKPD profiling and modelling; susceptibility/MIC testing and in-depth characterisation of antimicrobial activity; mechanism of action determination and ADME/PK assays.
Euprotec is based in Manchester (UK) operating out of state of the art laboratory facilities.
About Fulhold Ltd:
Fulhold is an international company based in Mauritius that is engaged in research and clinical trials in many parts of the world. This research aims to develop medicinal and nutritional applications for its patented active; Carbohydrate Derived Fulvic Acid (CHD-FA).
CHD-FA is a type of Fulvic Acid that is pure, concentrated and manufactured to exacting reference standards. CHD-FA does not suffer from the variable quality and contamination that prevent environmental sources of Fulvic Acid from being used in human medicine. CHD-FA is easy to formulate and shows synergistic activity with many actives that are no longer effective against drug resistant organisms.
Fulhold believes that CHD-FA will be a revolutionary active that will enable a number of innovative business strategies in human medicine.
For further information see www.fulhold.com
The Public Health Research Institute (PHRI) (www.phri.org) is a 72-year-old biomedical research organization that emphasizes translational approaches to overcome critical issues of infectious diseases. Founded in New York City, PHRI became an academic affiliate of the New Jersey Medical School-University of Medicine and Dentistry of New Jersey (UMDNJ) in 2006. PHRI’s 23 laboratories work on a wide range of infectious diseases issues including HIV and other viruses, TB, hospital and community acquired bacterial infections, fungal infections, biodefense and drug resistance. Fundamental knowledge of the disease process and its components is used to develop a new generation of diagnostics, therapeutics and vaccines. For more than 7 decades, PHRI’s culture of research innovation and excellence has led to important new discoveries in science and medicine.
About New Jersey Medical School -UMDNJ:
The University of Medicine and Dentistry of New Jersey (UMDNJ) is New Jersey’s only health sciences university with more than 6,000 students on five campuses attending three medical schools, the State’s only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and New Jersey’s only school of public health. UMDNJ operates University Hospital, a Level I Trauma Center in Newark, and University Behavioral HealthCare, which provides a continuum of healthcare services with multiple locations throughout the State.